FDA Announces All-Time Low User Fee Rates for Priority Review...
On Thursday, September 30th, FDA announced its user fee rates for fiscal…
Read Agency Alert
EMA Takes Steps to Minimize Animal Testing During Product Development
On Wednesday, September 29th, EMA announced the implementation of new measures indented…
Read Agency Alert
FDA Issues Product-Specific Guidance Documents for Chloroquine Phosphate and Hydroxychloroquine...
On Tuesday, April 14th, FDA released two product-specific guidance documents for chloroquine…
Read Agency Alert
FDA Requests all Zantac (Ranitidine) Products be Removed from the...
On Wednesday, April 1, 2020, FDA issued a statement asking all companies…
Read Agency Alert
Only 12% of Generic Drugs Reviewed Were Approved in the...
On August 7th, the U.S. Government Accountability Office (GAO) published its report…
Read Agency Alert
FDA Finalizes Guidance Concerning Premarket Tobacco Product Applications for E-Cigarettes
On, Tuesday, June 11th, 2019, the FDA issued a final guidance document…
Read Agency Alert
Improvements Are Coming to the Inactive Ingredient Database (IID)
In a new draft guidance released by the FDA on July 11th,…
Read Agency Alert
FDA Announces Update to Nonproprietary Naming Convention for Biosimilar Products
On Thursday, March 7th, FDA published a revised draft guidance, updating its…
Read Agency AlertYour Business has Complex Challenges. ProPharma Group has Exceptional Solutions.
We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.
Interested in gaining an industry edge? Let us help you stay up to date.
Sign up to receive updates and industry insights